
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Purple Biotech (PPBT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PPBT (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $34
1 Year Target Price $34
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.65% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.13M USD | Price to earnings Ratio - | 1Y Target Price 34 |
Price to earnings Ratio - | 1Y Target Price 34 | ||
Volume (30-day avg) 1 | Beta -0.58 | 52 Weeks Range 1.94 - 9.90 | Updated Date 08/29/2025 |
52 Weeks Range 1.94 - 9.90 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.9 |
Earnings Date
Report Date 2025-08-14 | When Before Market | Estimate -0.21 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -10.27% | Return on Equity (TTM) -8.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188503 | Price to Sales(TTM) 58.08 |
Enterprise Value 188503 | Price to Sales(TTM) 58.08 | ||
Enterprise Value to Revenue 33.08 | Enterprise Value to EBITDA -0.15 | Shares Outstanding 2648200 | Shares Floating 541350147 |
Shares Outstanding 2648200 | Shares Floating 541350147 | ||
Percent Insiders - | Percent Institutions 1.89 |
Upturn AI SWOT
Purple Biotech

Company Overview
History and Background
Purple Biotech Ltd., formerly Kitov Pharma, is a clinical-stage company focused on developing first-in-class therapies. It was founded in 2010 and has evolved its pipeline through internal development and acquisitions, focusing on oncology.
Core Business Areas
- Oncology Drug Development: Developing and commercializing oncology drugs for solid tumors and hematological malignancies.
Leadership and Structure
The leadership team includes experienced executives in drug development and finance. The company operates with a structure typical of small biotech firms, with focus on R&D and clinical trials.
Top Products and Market Share
Key Offerings
- CM24: A monoclonal antibody targeting CEACAM5, currently in clinical trials for solid tumors. Market share is not applicable as it's not commercialized. Competitors in the CEACAM5 targeting space are companies developing antibody-drug conjugates (ADCs) or other therapies targeting this pathway.
- NT219: A small molecule targeting IRS1/2, currently in clinical trials for solid tumors. Market share is not applicable as it's not commercialized. Competitors are companies developing inhibitors or modulators of the insulin receptor signaling pathway.
Market Dynamics
Industry Overview
The oncology market is a large and growing market, driven by an aging population and advancements in cancer therapies. The market is highly competitive, with numerous companies developing novel treatments.
Positioning
Purple Biotech is a clinical-stage biotech company attempting to develop innovative therapies. They are niche players targeting specific pathways. Their competitive advantage, if any, is based on the novelty and efficacy of their investigational drugs.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is estimated to be hundreds of billions of dollars. Purple Biotech targets niche indications; if CM24 and NT219 succeed, they would capture a small fraction of the overall TAM.
Upturn SWOT Analysis
Strengths
- Novel drug candidates (CM24 and NT219)
- Experienced leadership team
- Focus on specific oncology targets
Weaknesses
- Clinical-stage company with no approved products
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new oncology indications
Threats
- Clinical trial failures
- Competition from other oncology drugs
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AZN
Competitive Landscape
Purple Biotech is a very small player compared to major pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety with its investigational drugs.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by progression of clinical trials and securing financing. No product revenue yet.
Future Projections: Future growth depends on successful clinical trial outcomes, partnerships, and regulatory approvals. Analyst estimates are not available to generate at this time.
Recent Initiatives: Focus on advancing CM24 and NT219 through clinical trials. Exploring potential partnerships.
Summary
Purple Biotech is a clinical-stage company with no products on the market. Its valuation is almost entirely based on future expectations that its pipeline drugs pass trials and make it to market. This is speculative in nature. The company must successfully navigate clinical trials and raise capital for continued operations. Strong clinical data are needed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Third-party financial databases
Disclaimers:
This analysis is based on available information and is not financial advice. Investments in biotech companies are highly speculative and involve significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Purple Biotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://purple-biotech.com |
Full time employees 9 | Website https://purple-biotech.com |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.